Xiaoyong Wang

Xiaoyong Wang

Auto-generated profile, based on publicly available information

Xiaoyong Wang

Department of Food and Animal Sciences, Tennessee State University, Nashville, TN 37209, USA; Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2022 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
LZLijuan Zhang
Lijuan Zhang
XWXiaoyong Wang
Xiaoyong Wang
HSHongwei Si
Hongwei Si

21 July 2022 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
VNVerra M. Ngwa
Verra M. Ngwa
DEDeanna N. Edwards
Deanna N. Edwards
YHYoonha Hwang
Yoonha Hwang
BKBreelyn Karno
Breelyn Karno
XWXiaoyong Wang
Xiaoyong Wang
JCJin Chen
Jin Chen
Glutamine is the most abundant nonessential amino acid in blood stream; yet its concentration in tumor interstitium is markedly lower than that in the serum, reflecting the huge demand of various cell types in tumor microenvironment for glutamine. While many studies have investigated glutamine metabolism in tumor epithelium and infiltrating immune cells, the role of glutamine metabolism in tumor blood vessels remains unknown. Here, we report that inducible genetic deletion of glutaminase (GLS) specifically in host endothelium, GLSECKO, impairs tumor growth and metastatic dissemination in vivo. Loss of GLS decreased tumor microvascular density, increased perivascular support cell coverage, improved perfusion, and reduced hypoxia in mammary tumors. Importantly, chemotherapeutic drug delivery and therapeutic efficacy were improved in tumor-bearing GLSECKO hosts or in combination with GLS inhibitor, CB-839. Mechanistically, loss of GLS in tumor endothelium resulted in decreased leptin levels, and exogenous recombinant leptin rescued tumor growth defects in GLSECKO mice. Together, these data demonstrate that inhibition of endothelial glutamine metabolism normalizes tumor vessels, reducing tumor growth and metastatic spread, improving perfusion, reducing hypoxia, and enhancing chemotherapeutic delivery. Thus, targeting glutamine metabolism in host vasculature may improve clinical outcome in patients with solid tumors.Significance: This study demonstrates a crucial role for glutamine metabolism in tumor endothelium, which may be exploited therapeutically to induce vascular normalization and improve drug delivery in solid tumors.

6 August 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
XWXiaoyong Wang
Xiaoyong Wang
LZLijuan Zhang
Lijuan Zhang
HSHongwei Si
Hongwei Si
Combining two or more chemicals in chemotherapy is rapidly increasing because of its higher efficacy, lower toxicity, lower dosages, and lower drug resistance. Here, we identified a novel combination of luteolin (LUT) and curcumin (CUR), two bioactive compounds from foods, synergistically suppressed triple-negative breast cancer (TNBC) cell proliferation (LUT 30 µM + CUR 20 µM), colony formation (LUT 1 µM + CUR 2 µM), and tumor growth in xenograft mice (LUT 10 mg/kg body weight/day + CUR 20 mg/kg body weight/day, i.p. injection every other day, 5 weeks), while the individual chemical alone did not show these inhibitory effects significantly at the selected concentrations/dosages. Our total RNA transcriptome analysis in xenograft tumors revealed that combining LUT and CUR synergistically activated type I interferon (IFN) signaling and suppressed transforming growth factor-beta (TGF-β) signaling pathways, which was further confirmed by the expression/activity of several proteins of the pathways in tumors. In addition, this combination of LUT and CUR also synergistically decreased oncoprotein levels of c-Myc and Notch1, the critical molecules required to maintain stem cell properties, tumor clonal evolution, and drug resistance. These results suggest that the combination of LUT and CUR synergistically inhibits TNBC by suppressing multiple cellular mechanisms, such as proliferation, colony formation, and transformation, as well as tumor migration, invasion, and metastasis, via regulating IFN and TGF-β signaling pathways. Therefore, combining LUT and CUR may be an effective therapeutic agent to treat highly aggressive, drug-resistant TNBC patients after clinical trials.

4 April 2023
Verified
Other
Open access
VNVerra M. Ngwa
Verra M. Ngwa
DEDeanna N. Edwards
Deanna N. Edwards
YHYoonha Hwang
Yoonha Hwang
BKBreelyn Karno
Breelyn Karno
XWXiaoyong Wang
Xiaoyong Wang
JCJin Chen
Jin Chen
Glutamine is the most abundant nonessential amino acid in blood stream; yet its concentration in tumor interstitium is markedly lower than that in the serum, reflecting the huge demand of various cell types in tumor microenvironment for glutamine. While many studies have investigated glutamine metabolism in tumor epithelium and infiltrating immune cells, the role of glutamine metabolism in tumor blood vessels remains unknown. Here, we report that inducible genetic deletion of glutaminase (GLS) specifically in host endothelium, GLSECKO, impairs tumor growth and metastatic dissemination in vivo. Loss of GLS decreased tumor microvascular density, increased perivascular support cell coverage, improved perfusion, and reduced hypoxia in mammary tumors. Importantly, chemotherapeutic drug delivery and therapeutic efficacy were improved in tumor-bearing GLSECKO hosts or in combination with GLS inhibitor, CB-839. Mechanistically, loss of GLS in tumor endothelium resulted in decreased leptin levels, and exogenous recombinant leptin rescued tumor growth defects in GLSECKO mice. Together, these data demonstrate that inhibition of endothelial glutamine metabolism normalizes tumor vessels, reducing tumor growth and metastatic spread, improving perfusion, reducing hypoxia, and enhancing chemotherapeutic delivery. Thus, targeting glutamine metabolism in host vasculature may improve clinical outcome in patients with solid tumors.Significance:This study demonstrates a crucial role for glutamine metabolism in tumor endothelium, which may be exploited therapeutically to induce vascular normalization and improve drug delivery in solid tumors.

2 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SCShu-Ting Chou
Shu-Ting Chou
XWXiaoyong Wang
Xiaoyong Wang
JYJing Yang
Jing Yang
YHYoonha Hwang
Yoonha Hwang
JWJiacheng Wang
Jiacheng Wang
JCJin Chen
Jin Chen
Distant metastasis is the leading cause of cancer-related mortality, yet how tumor-intrinsic metabolic enzymes regulate tumor-immune crosstalk during metastasis remains poorly understood. Using an in vivo CRISPR-Cas9 screen targeting metabolic genes in an orthotopic 4T1 mammary carcinoma model, we identified arginase 2 (ARG2) as a lymphocyte-dependent suppressor of lung metastasis. Loss of ARG2 enhanced spontaneous lung metastasis without affecting primary tumor growth or metastatic outgrowth following intravenous tumor cell injection, indicating a role in early metastatic dissemination. Mechanistically, ARG2 deficiency increased nitric oxide synthase 2 (NOS2) expression, nitric oxide production, cytosolic DNA accumulation, and activation of the cGAS-STING-NF-κB pathway, leading to inflammatory cytokine production. ARG2-deficient tumors exhibited enrichment of Th17 cells and reduced anti-tumor immune populations. Genetic deletion of NOS2 reversed these immune alterations and suppressed metastasis. Together, these findings identify a tumor cell-intrinsic ARG2-NOS2 axis that promotes metastasis through inflammatory remodeling of the tumor microenvironment.